Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59244
Forster, M D; Dedes, K J; Sandhu, S; Frentzas, S; Kristeleit, R; Ashworth, A; Poole, C J; Weigelt, B; Kaye, S B; Rhoda Molife, L (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, 8(5):302-306.
PDF - Registered users only
View at publisher
On the basis of her sensitivity to repeated platinum treatment she was treated with the oral poly(ADP)-ribose polymerase (PARP) 1 inhibitor olaparib as part of a phase I trial. Repeat MRI scan at week 10 of treatment showed a significant reduction in the size of the brain metastases without steroid treatment or radiotherapy and the patient reported subjective improvement in tumor-related symptoms. After 8 months of olaparib treatment the patient developed objective disease progression. The tumor biopsy was negative for somatic BRCA1 and BRCA2 mutations, but displayed loss of PTEN, which has been suggested to be another predictive marker for sensitivity to PARP inhibitors. The patient remained alive for 10 months after completing olaparib, having gone on to derive further clinical benefit from repeat exposure to platinum-based therapy.
2 downloads since deposited on 17 Feb 2012
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology|
|DDC:||610 Medicine & health|
|Deposited On:||17 Feb 2012 09:27|
|Last Modified:||26 Dec 2013 08:08|
|Publisher:||Nature Publishing Group|
|ISSN:||1759-4774 (P) 1759-4782 (E)|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page